Compare Brunswick Corporation (BC) vs Eli Lilly And Co (LLY) Price & Performance

BC trades at $80.43, down 1.37% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $1.56 versus $1.19 estimated, and the company maintains a dividend payout. Despite negative net income margins and ROE, revenue trends show stabilization, and cash flow from operations remains positive at $562.10M for 2025.

The outlook is cautiously optimistic, driven by earnings beats and a consensus price target of $85.33, but risks include persistent unprofitability and high debt levels. Investors may find opportunity in the bullish technical setup and institutional buying, though margin pressures and competitive challenges warrant close monitoring.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.